Gerwyn Morris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3790971/publications.pdf

Version: 2024-02-01

63	3,822	117625	133252
papers	citations	34 h-index	59 g-index

63	63	63	5450
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 114, 110481.	4.8	6
2	Increased ACE2, sRAGE, and Immune Activation, but Lowered Calcium and Magnesium in COVID-19. Recent Advances in Inflammation & Allergy Drug Discovery, 2022, 16, 32-43.	0.8	10
3	Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia. Molecular Neurobiology, 2022, 59, 3485-3503.	4.0	19
4	Preventing the development of severe COVID-19 by modifying immunothrombosis. Life Sciences, 2021, 264, 118617.	4.3	40
5	The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. Neuroscience and Biobehavioral Reviews, 2021, 125, 244-263.	6.1	29
6	Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 7164.	4.1	11
7	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. Cytokine, 2021, 144, 155593.	3.2	61
8	The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. Pharmacological Research, 2021, 170, 105729.	7.1	24
9	Polyphenols as adjunctive treatments in psychiatric and neurodegenerative disorders: Efficacy, mechanisms of action, and factors influencing inter-individual response. Free Radical Biology and Medicine, 2021, 172, 101-122.	2.9	19
10	The lipid paradox in neuroprogressive disorders: Causes and consequences. Neuroscience and Biobehavioral Reviews, 2021, 128, 35-57.	6.1	10
11	Statins: Neurobiological underpinnings and mechanisms in mood disorders. Neuroscience and Biobehavioral Reviews, 2021, 128, 693-708.	6.1	15
12	Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry. Molecular Neurobiology, 2021, 58, 2158-2182.	4.0	48
13	The role of microglia in neuroprogressive disorders: mechanisms and possible neurotherapeutic effects of induced ketosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 99, 109858.	4.8	26
14	Endothelial dysfunction in neuroprogressive disordersâ€"causes and suggested treatments. BMC Medicine, 2020, 18, 305.	5.5	53
15	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. Life Sciences, 2020, 262, 118541.	4.3	12
16	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. Life Sciences, 2020, 258, 118166.	4.3	79
17	The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it?. Molecular Biology Reports, 2020, 47, 5587-5620.	2.3	29
18	Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought?. International Journal of Neuropsychopharmacology, 2020, 23, 366-384.	2.1	28

#	Article	IF	Citations
19	Nutritional ketosis as an intervention to relieve astrogliosis: Possible therapeutic applications in the treatment of neurodegenerative and neuroprogressive disorders. European Psychiatry, 2020, 63, e8.	0.2	31
20	Do Human Endogenous Retroviruses Contribute to Multiple Sclerosis, and if So, How?. Molecular Neurobiology, 2019, 56, 2590-2605.	4.0	33
21	The compensatory antioxidant response system with a focus on neuroprogressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109708.	4.8	19
22	Is a diagnostic blood test for chronic fatigue syndrome on the horizon?. Expert Review of Molecular Diagnostics, 2019, 19, 1049-1051.	3.1	8
23	Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities. Pharmacological Research, 2019, 148, 104450.	7.1	31
24	Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders. Neuroscience and Biobehavioral Reviews, 2019, 107, 862-882.	6.1	74
25	Emerging role of innate B1 cells in the pathophysiology of autoimmune and neuroimmune diseases: Association with inflammation, oxidative and nitrosative stress and autoimmune responses. Pharmacological Research, 2019, 148, 104408.	7.1	35
26	Socioeconomic Deprivation, Adverse Childhood Experiences and Medical Disorders in Adulthood: Mechanisms and Associations. Molecular Neurobiology, 2019, 56, 5866-5890.	4.0	46
27	Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?. Metabolic Brain Disease, 2019, 34, 385-415.	2.9	50
28	Could Alzheimerâ€™s Disease Originate in the Periphery and If So How So?. Molecular Neurobiology, 2019, 56, 406-434.	4.0	71
29	Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. Molecular Neurobiology, 2018, 55, 4195-4206.	4.0	279
30	The Endoplasmic Reticulum Stress Response in Neuroprogressive Diseases: Emerging Pathophysiological Role and Translational Implications. Molecular Neurobiology, 2018, 55, 8765-8787.	4.0	59
31	The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. Sleep Medicine Reviews, 2018, 41, 255-265.	8.5	85
32	Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases. Behavioural Brain Research, 2018, 341, 154-175.	2.2	114
33	Multiple Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways Explain the Frequent Presence of Depression in Multiple Sclerosis. Molecular Neurobiology, 2018, 55, 6282-6306.	4.0	51
34	A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause?. Molecular Neurobiology, 2018, 55, 3592-3609.	4.0	25
35	The Putative Role of Environmental Mercury in the Pathogenesis and Pathophysiology of Autism Spectrum Disorders and Subtypes. Molecular Neurobiology, 2018, 55, 4834-4856.	4.0	22
36	Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. Molecular Neurobiology, 2018, 55, 5767-5786.	4.0	114

#	Article	IF	Citations
37	Post-Operative Cognitive Dysfunction: An exploration of the inflammatory hypothesis and novel therapies. Neuroscience and Biobehavioral Reviews, 2018, 84, 116-133.	6.1	210
38	The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases. Neuroscience and Biobehavioral Reviews, 2018, 84, 453-469.	6.1	27
39	Leaky brain in neurological and psychiatric disorders: Drivers and consequences. Australian and New Zealand Journal of Psychiatry, 2018, 52, 924-948.	2.3	90
40	Imaging genetics paradigms in depression research: Systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 102-113.	4.8	19
41	Potential therapeutic interventions based on the role of the endoplasmic reticulum stress response in progressive neurodegenerative diseases. Neural Regeneration Research, 2018, 13, 1887.	3.0	7
42	The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease. Molecular Neurobiology, 2017, 54, 4432-4451.	4.0	191
43	Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome. Molecular Neurobiology, 2017, 54, 4271-4291.	4.0	82
44	A model of the mitochondrial basis of bipolar disorder. Neuroscience and Biobehavioral Reviews, 2017, 74, 1-20.	6.1	118
45	The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved?. Metabolic Brain Disease, 2017, 32, 1335-1355.	2.9	57
46	Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways. Molecular Neurobiology, 2017, 54, 6806-6819.	4.0	77
47	The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases. Molecular Neurobiology, 2016, 53, 1195-1219.	4.0	115
48	The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability. Molecular Neurobiology, 2016, 53, 2550-2571.	4.0	28
49	The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders. Molecular Neurobiology, 2016, 53, 4638-4658.	4.0	49
50	Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Medicine, 2015, 13, 28.	5.5	121
51	The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Medicine, 2015, 13, 68.	5.5	186
52	The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue. CNS and Neurological Disorders - Drug Targets, 2015, 14, 838-854.	1.4	39
53	Mitochondrial dysfunctions in Myalgic Encephalomyelitis / chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metabolic Brain Disease, 2014, 29, 19-36.	2.9	109
54	The Glutathione System: A New Drug Target in Neuroimmune Disorders. Molecular Neurobiology, 2014, 50, 1059-1084.	4.0	164

#	Article	IF	Citations
55	Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). Current Neuropharmacology, 2014, 12, 168-185.	2.9	103
56	A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metabolic Brain Disease, 2013, 28, 523-540.	2.9	92
57	A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Medicine, 2013, 11, 64.	5.5	62
58	Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Medicine, 2013, 11, 205.	5.5	121
59	Case definitions and diagnostic criteria for Myalgic Encephalomyelitis and Chronic fatigue Syndrome: from clinical-consensus to evidence-based case definitions. Neuroendocrinology Letters, 2013, 34, 185-99.	0.2	22
60	Increased nuclear factor-ÎºB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Medical Hypotheses, 2012, 79, 607-613.	1.5	49
61	DecreasedC-MYCandBCL2Expression Correlates with Methylprednisolone-Mediated Inhibition of Raji Lymphoma Growth. Biochemical and Molecular Medicine, 1997, 60, 108-115.	1.4	4
62	Neutralization of bleomycin hydrolase by an epitope-specific antibody. Molecular Pharmacology, 1992, 42, 57-62.	2.3	6
63	Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells. Biochemical Pharmacology, 1991, 41, 1559-1566.	4.4	8